<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Protein C, concentrate from human plasma: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Protein C, concentrate from human plasma: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Protein C, concentrate from human plasma: Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="11888" href="/d/html/11888.html" rel="external">see "Protein C, concentrate from human plasma: Patient drug information"</a> and <a class="drug drug_pediatric" data-topicid="16776" href="/d/html/16776.html" rel="external">see "Protein C, concentrate from human plasma: Pediatric drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F4594766"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Ceprotin</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F4594770"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Blood Product Derivative;</li>
<li>
                        Enzyme;</li>
<li>
                        Protein C</li></ul></div>
<div class="block doa drugH1Div" id="F4595363"><span class="drugH1">Dosing: Adult</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Patient variables (including age, clinical condition, severity of protein C deficiency, and plasma levels of protein C) will influence dosing and duration of therapy. Individualize frequency, duration, and dose based on protein C activity and patient pharmacokinetic profile.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="4a7d6a40-e99a-4dd9-aa5a-82e3f7cb4ab6">Severe congenital protein C deficiency</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Severe congenital protein C deficiency: IV:</b></p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Note:</b> Maintain target peak protein C activity of 100% during acute episodes and short-term prophylaxis. After resolution of the acute episode or for long-term prophylaxis, maintain trough levels of protein C activity &gt;25%. Higher peak levels of protein C may be necessary in prophylactic therapy of patients at increased risk for thrombosis (eg, infection, trauma, surgical intervention). If a patient is switched to a vitamin K antagonist, continue protein C replacement until stable anticoagulation is obtained. Initiate the vitamin K antagonist at a low dose and adjust incrementally, rather than using a loading dose.</p>
<p style="text-indent:-2em;margin-left:4em;">Acute episode/short-term prophylaxis:</p>
<p style="text-indent:-2em;margin-left:6em;">Initial dose: <b>IV:</b> 100 to 120 units/kg (for determination of recovery and half-life).</p>
<p style="text-indent:-2em;margin-left:6em;">Subsequent 3 doses: <b>IV: </b>60 to 80 units/kg every 6 hours (adjust to maintain peak protein C activity of 100%).</p>
<p style="text-indent:-2em;margin-left:6em;">Maintenance dose: <b>IV: </b>45 to 60 units/kg every 6 or 12 hours (adjust to maintain recommended maintenance trough protein C activity levels &gt;25%).</p>
<p style="text-indent:-2em;margin-left:4em;">Long-term prophylaxis: Maintenance dose: <b>IV: </b>45 to 60 units/kg every 12 hours (recommended maintenance trough protein C activity levels &gt;25%).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50991084"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling (has not been studied); monitor closely for sodium overload.</p></div>
<div class="block doha drugH1Div" id="F50988245"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer’s labeling (has not been studied).</p></div>
<div class="block dop drugH1Div" id="F4595362"><span class="drugH1">Dosing: Pediatric</span><p>(For additional information <a class="drug drug_pediatric" data-topicid="16776" href="/d/html/16776.html" rel="external">see "Protein C, concentrate from human plasma: Pediatric drug information"</a>)</p>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Patient variables (including age, clinical condition, and plasma levels of protein C) will influence dosing and duration of therapy. Individualize dosing based on protein C activity and patient's pharmacokinetic profile.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="4a7d6a40-e99a-4dd9-aa5a-82e3f7cb4ab6">Severe congenital protein C deficiency</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Severe congenital protein C deficiency:</b> Infants, Children, and Adolescents:</p>
<p style="text-indent:-2em;margin-left:4em;">Acute episode/short-term prophylaxis:</p>
<p style="text-indent:-2em;margin-left:6em;">Initial dose: IV: 100 to 120 units/kg/dose (for determination of recovery and half-life) followed by subsequent 3 doses: 60 to 80 units/kg/dose every 6 hours adjusted to maintain peak protein C activity of 100%.</p>
<p style="text-indent:-2em;margin-left:6em;">Maintenance dose: IV: 45 to 60 units/kg/dose every 6 or 12 hours adjusted to maintain recommended maintenance trough protein C activity levels &gt;25%. Continue until desired anticoagulation achieved.</p>
<p style="text-indent:-2em;margin-left:4em;">Long-term prophylaxis: Maintenance dose: IV: 45 to 60 units/kg/dose every 12 hours (recommended maintenance trough protein C activity levels &gt;25%).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Maintain target peak protein C activity of 100% during acute episodes and short-term prophylaxis. Maintain trough levels of protein C activity &gt;25%. Higher peak levels of protein C may be necessary in prophylactic therapy of patients at increased risk for thrombosis (eg, infection, trauma, surgical intervention).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="c2dfd839-3638-40d6-b587-4040f524e3ec">Purpura fulminans secondary to meningococcemia</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Purpura fulminans secondary to meningococcemia:</b> Limited data available; optimal dose not established; role in management is not defined (Fuhrman 2017):</p>
<p style="text-indent:-2em;margin-left:4em;">Infants, Children, and Adolescents: IV: 100 to 150 units/kg/dose every 6 hours for 72 hours, followed by 50 to 150 units/kg/dose every 12 hours (de Kleijn 2003; Fourier 2003). Other protocols have reported a daily dose of 100 units/kg/day with doses divided every 4 to 6 hours or as a continuous infusion (Veldman 2010) and others used a loading dose (100 units/kg/dose) followed by a continuous infusion (initial rate: 10 units/kg/hour) with titration of rate based upon protein C levels (target: 80 to 120 units/mL) (White 2000). Duration of therapy variable (1 to 24 days) (Veldman 2010); activated protein C levels and clinical response should be closely monitored.</p>
<p style="text-indent:-2em;margin-left:6em;">Dosing based on placebo-controlled trials and retrospective reviews. In a phase II, double-blind, placebo-controlled, dose-finding study of 40 pediatric patients (median age: 2.3 years [range: 2.4 months to 16.1 years]), a dose of 100 to 150 units/kg/dose every 6 hours for 72 hours followed by 50 to 150 units/kg/dose every 12 hours until target symptom/sign resolution or treatment duration reaches 7 days was used; results showed dose-related increases in plasma activated protein C and resolution of coagulation imbalances (de Kleijn 2003). A retrospective review of 94 pediatric patients (newborn to 18 years) reported a median dose of 100 units/kg/day divided every 4 to 6 hours (daily dose range: 28 to 375 units/kg/day) in the majority of patients (78 of the 94 patients); the remaining patients received an initial bolus with the remainder of daily dose administered as a continuous IV infusion (dosing specifics were not provided); median treatment duration of 33 hours (range: 1 to 645 hours) (Veldman 2010). An open-label, prospective study of 36 patients (3 months to 72 years) reported an initial dose of 100 units/kg followed by a continuous IV infusion with an initial rate of 10 units/kg/hour adjusted daily to maintain plasma protein C concentration 80 to 120 units/mL (White 2000).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dorp drugH1Div" id="F51159517"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling (has not been studied); monitor closely for sodium overload.</p></div>
<div class="block dohp drugH1Div" id="F51159518"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).</p></div>
<div class="block adr drugH1Div" id="F4595341"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions are derived from product labeling unless otherwise specified. Reported adverse reactions are for pediatric patients and adults.</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined:</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Major hemorrhage</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Hypersensitivity reaction</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Dizziness</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Diaphoresis</p>
<p style="text-indent:-2em;margin-left:4em;">Local: Injection-site reaction</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Restlessness</p></div>
<div class="block coi drugH1Div" id="F4595337"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">There are no contraindications listed in the manufacturer’s labeling.</p></div>
<div class="block war drugH1Div" id="F4595338"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Heparin-induced thrombocytopenia (HIT): Trace amounts of heparin contained within the formulation may lead to HIT; evaluate platelet counts if HIT is suspected.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hypersensitivity reactions: May contain trace amounts of mouse protein and/or heparin. Discontinue use in the presence of hypersensitivity/allergic reactions.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Renal impairment: Use with caution in patients with renal impairment; monitor patients closely for sodium overload.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Special populations:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Sodium-restricted patients: Use with caution in patients where sodium restriction is necessary.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Dosage form specific issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Human plasma: Product of human plasma; may potentially contain infectious agents which could transmit disease; screening of donors, as well as testing and/or inactivation or removal of certain viruses, reduces this risk. Infections thought to be transmitted by this product should be reported to the manufacturer.</p></div>
<div class="block foc drugH1Div" id="F4595369"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Reconstituted, Intravenous [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Ceprotin: 500 units (1 ea); 1000 units (1 ea) [contains albumin human, heparin, mouse (murine) and/or hamster protein]</p></div>
<div class="block geq drugH1Div" id="F4594768"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">No</p></div>
<div class="block fee drugH1Div" id="F16324135"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution (reconstituted)</b> (Ceprotin Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">500 unit (Price provided is per AHF Unit): $1.80</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">1000 unit (Price provided is per AHF Unit): $1.80</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block adm drugH1Div" id="F4595365"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">IV: Administer by intravenous injection at a rate not to exceed 2 mL/minute. In infants and children &lt;10 kg, administration should not exceed a rate of 0.2 mL/kg/minute. Administration must be completed within 3 hours of solution preparation.</p></div>
<div class="block admp drugH1Div" id="F52614244"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Parenteral: Administer by IV injection; infusion must be completed within 3 hours of solution preparation.</p>
<p style="text-indent:-2em;margin-left:2em;">Neonates, Infants, and Children &lt;10 kg: Rate should not exceed 0.2 mL/kg/minute</p>
<p style="text-indent:-2em;margin-left:2em;">Children ≥10 kg and Adolescents: Rate should not exceed 2 mL/minute</p></div>
<div class="block use drugH1Div" id="F4594771"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:0em;display:inline">
<b>Severe congenital protein C deficiency:</b> Prevention and treatment of venous thrombosis and purpura fulminans in adults and pediatric patients with severe congenital protein C deficiency.</p></div>
<div class="block mst drugH1Div" id="F4594763"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues: </span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Ceprotin may be confused with aprotinin, Cipro</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Protein C concentrate (human) may be confused with activated protein C (human, recombinant) which refers to drotrecogin alfa</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F13299957"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F4595347"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Anticoagulants: Protein C Concentrate (Human) may enhance the anticoagulant effect of Anticoagulants. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Thrombolytic Agents: Protein C Concentrate (Human) may enhance the adverse/toxic effect of Thrombolytic Agents. Specifically, the risk of bleeding may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vitamin K Antagonists (eg, warfarin): Protein C Concentrate (Human) may enhance the adverse/toxic effect of Vitamin K Antagonists. Specifically, the risk of warfarin-induced skin necrosis may be increased. Protein C Concentrate (Human) may diminish the therapeutic effect of Vitamin K Antagonists. This is effect is transient and occurs at the initiation of vitamin K antagonist therapy. <i> Risk C: Monitor therapy</i></p></div>
<div class="block pri drugH1Div" id="F4595333"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;display:inline">Protein C Concentrate is derived from purified human plasma.</p></div>
<div class="block brc drugH1Div" id="F4595336"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">Protein C Concentrate is derived from purified human plasma.</p>
<p style="text-indent:-2em;margin-left:2em;">According to the manufacturer, the decision to breastfeed during therapy should consider the risk of infant exposure, the benefits of breastfeeding to the infant, and benefits of treatment to the mother.</p></div>
<div class="block dic drugH1Div" id="F4595364"><span class="drugH1">Dietary Considerations</span>
<p style="text-indent:0em;display:inline">At maximum daily doses, product formulation contains sodium &gt;200 mg.</p></div>
<div class="block mop drugH1Div" id="F4595367"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Protein C activity (chromogenic assay) prior to and during therapy; signs and symptoms of bleeding; hemoglobin/hematocrit, PT/INR, platelet count; signs and symptoms of sodium overload in patients with renal impairment.</p></div>
<div class="block rer drugH1Div" id="F4595355"><span class="drugH1">Reference Range</span>
<p style="text-indent:0em;display:inline">Maintain target peak protein C activity of 100% during acute episodes and short-term prophylaxis. After resolution of the acute episode or for long-term prophylaxis, maintain trough levels of protein C activity &gt;25%. Higher peak levels of protein C may be necessary in prophylactic therapy of patients at increased risk for thrombosis (eg, infection, trauma, surgical intervention).</p></div>
<div class="block pha drugH1Div" id="F4595353"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Converted to activated protein C (APC). APC is a serine protease which inactivates factors Va and VIIIa, limiting thrombotic formation. <i>In vitro </i>data also suggest inhibition of plasminogen activator inhibitor-1 (PAF-1) resulting in profibrinolytic activity, inhibition of macrophage production of tumor necrosis factor, blocking of leukocyte adhesion, and limitation of thrombin-induced inflammatory responses.</p></div>
<div class="block phk drugH1Div" id="F4595356"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Note: </b>Limited data suggests that infants and very young children may have a faster clearance, lower AUC and maximum serum concentration, larger volume of distribution, and shorter half-life than older subjects. </p>
<p style="text-indent:-2em;margin-left:2em;">Onset of action: 30 minutes </p>
<p style="text-indent:-2em;margin-left:2em;">Distribution: V<sub>d</sub>: Median: 0.074L/kg (range: 0.044 to 0.165 L/kg) </p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Activated protein C (APC) inactivated by plasma protease inhibitors</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: Median: 9.8 hours; range: 4.9 to 14.7 hours</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak, plasma: T<sub>max</sub>: 0.5 hours; range: 0.17 to 1.33 hours</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F5539986"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Ceprotin</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Ceprotin</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Ceprotin</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Ceprotin</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Ceprotin</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Ceprotin</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Ceprotin</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Ceprotin | Protexel</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Ceprotin</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Ceprotin</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Ceprotin</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Anact c | Anact c teijin</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Ceprotin</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Ceprotin</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Ceprotin</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Ceprotin</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Ceprotin</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Ceprotin</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Ceprotin</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Ceprotin</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Ceprotin</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Ceprotin</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Ceprotin</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Ceprotin</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-Ceprotin.1">
<a name="Ceprotin.1"></a>Ceprotin (protein C concentrate) [prescribing information]. Lexington, MA: Takeda Pharmaceuticals USA Inc; March 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12794428">
<a name="12794428"></a>de Kleijn ED, de Groot R, Hack CE, et al, "Activation of Protein C Following Infusion of Protein C Concentrate in Children With Severe Meningococcal Sepsis and Purpura Fulminans: A Randomized, Double-Blinded, Placebo-Controlled, Dose-Finding Study," <i>Crit Care Med</i>, 2003, 31(6):1839-47.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/protein-c-concentrate-from-human-plasma-drug-information/abstract-text/12794428/pubmed" id="12794428" target="_blank">12794428</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12761614">
<a name="12761614"></a>Fourrier F, Leclerc F, Aidan K, et al. Combined antithrombin and protein C supplementation in meningococcal purpura fulminans: a pharmacokinetic study. <i>Intensive Care Med</i>. 2003;29(7):1081-1087.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/protein-c-concentrate-from-human-plasma-drug-information/abstract-text/12761614/pubmed" id="12761614" target="_blank">12761614</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Fuhrman B, Zimmerman J, eds.<i> Pediatric Critical Care</i>. 5th ed. Philadelphia, PA: Elsevier Health; 2017.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20723255">
<a name="20723255"></a>Veldman A, Fischer D, Wong FY, et al, "Human Protein C Concentrate in the Treatment of Purpura Fulminans: A Retrospective Analysis of Safety and Outcome in 94 Pediatric Patients," <i>Crit Care</i>, 2010, 14(4):R156.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/protein-c-concentrate-from-human-plasma-drug-information/abstract-text/20723255/pubmed" id="20723255" target="_blank">20723255</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11090052">
<a name="11090052"></a>White B, Livingstone W, Murphy C, et al, "An Open-Label Study of the Role of Adjuvant Hemostatic Support With Protein C Replacement Therapy in Purpura Fulminans-Associated Meningococcemia," <i>Blood</i>, 2000, 96(12):3719-24.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/protein-c-concentrate-from-human-plasma-drug-information/abstract-text/11090052/pubmed" id="11090052" target="_blank">11090052</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 10094 Version 165.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
